Related Experiment Video
Updated: Oct 1, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors
Steven B Maron1, Samuel J Klempner2
1Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Summary:
Optimizing the utility of tumor mutational burden in solid tumors remains an unmet need and a clinical knowledge gap. Using a centrally determined cutoff of ≥16 mut/Mb, Friedman and colleagues demonstrate an ability to enrich for atezolizumab response in a pretreated pan-cancer multibasket study. See related article by Friedman et al., p. 654 (4).
Related Concept Videos
Tumor Immunotherapy
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

